Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea.
Important sources of oxytocin and vasopressin in the human, apart from the supraoptic and paraventricular nuclei of the brain, may be the fetus during labor as well as the endometrium and decidua of the uterus itself. The release of oxytocin and vasopressin to plasma is under influence of ovarian steroids. The two hormones stimulate uterine contractions in pregnant and non-pregnant women via myometrial oxytocin and vasopressin V1a receptors. At the onset of human labor preterm or at term no clear rise in the maternal plasma concentration of oxytocin and/or vasopressin has been demonstrated, but there may be an increased pulse frequency of the release of oxytocin to plasma with the advance of labor. Vasopressin is more potent than oxytocin on isolated myometrium from women undergoing Cesarean section at term. The myometrial concentration of the two receptors is about equal. At the onset of labor preterm and at term there is a tendency to an increase in the density of oxytocin and vasopressin V1a receptors, but there may be a heterogeneous expression of at least the former receptor between different myometrial cells. In advanced labor or after oxytocin treatment the receptors are markedly downregulated. The importance of oxytocin and vasopressin in mechanisms of preterm labor is confirmed by the therapeutic effect in the condition of the oxytocin and vasopressin V1a receptor blocking oxytocin analogue, atosiban. In women with primary dysmenorrhea the plasma concentration of vasopressin is elevated. The in vivo effect of vasopressin on uterine activity in non-pregnant women is about five times more pronounced than that of oxytocin, and it increases premenstrually. Correspondingly, the density of vasopressin V1a and oxytocin receptors vary to the same degree, and a premenstrual rise in the former receptor is seen. Atosiban and the non-peptide compound, SR 49059, which binds to the two receptors in a similar way as atosiban, are therapeutically effective in dysmenorrhea.
Akerlund
Mats
M
Department of Obstetrics and Gynecology, University Hospital, S-221 85 Lund, Sweden. mats.akerlund@gyn.lu.se
D004412:Dysmenorrhea / Q000503:physiopathology*; D005260:Female; D006801:Humans; D007752:Obstetric Labor, Premature / Q000503:physiopathology*; D010121:Oxytocin / Q000378:metabolism / Q000502:physiology*; D011247:Pregnancy; D017483:Receptors, Vasopressin / Q000502:physiology; D014599:Uterus / Q000502:physiology / Q000503:physiopathology; D014667:Vasopressins / Q000378:metabolism / Q000502:physiology*
D017483:Receptors, Vasopressin; D014667:Vasopressins; D010121:Oxytocin